SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: reaper247, BottomWatcher , Eltp, fuzzymcilwoods, FIN85, ninersax
Search This Board: 
Last Post: 7/23/2017 4:23:31 PM - Followers: 162 - Board type: Free - Posts Today: 22

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 





 


https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12149068

AEPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP News: Amended Statement of Changes in Beneficial Ownership (4/a) 07/06/2017 06:13:58 PM
AEPP News: Amended Statement of Beneficial Ownership (3/a) 07/06/2017 04:38:19 PM
AEPP News: Current Report Filing (8-k) 06/28/2017 03:11:58 PM
AEPP News: Quarterly Report (10-q) 05/15/2017 06:12:06 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/28/2017 11:44:59 AM
PostSubject
#8211  Sticky Note Perhaps, but still extremely conservative price projections IMO. zen222 07/23/17 10:32:42 AM
#8154  Sticky Note ...prior officers of AEPP, including Brian Kistler, resigned fuzzymcilwoods 07/21/17 04:04:17 PM
#8084  Sticky Note AEPP/Oncolix summary. reaper247 07/20/17 06:32:22 PM
#7989  Sticky Note 7 trading days or less until Christmas!!!! Man DayDreeming 07/19/17 05:35:49 PM
#6368  Sticky Note "NO PLANS TO REVERSE SPLIT" AND REVERSE MERGER DayDreeming 06/28/17 03:19:23 PM
#8224   GLAD I HAVE MY SHARES NOW!!! I DON'T_WANT_TO_BE_CHASING_AEPP_UP_AFTER_R/M_IS_AN Rat Fink 07/23/17 04:23:31 PM
#8223   Technically NO DOUBT about that explosion. WOW! retiredtech 07/23/17 04:14:49 PM
#8222   Thanks for the update from Redman. I tmcfo 07/23/17 02:10:15 PM
#8221   So at least we know from his response dabullishbear 07/23/17 02:02:08 PM
#8220   Great analysis..both trends are pointing to positive price tmcfo 07/23/17 01:54:46 PM
#8219   My email to Redman today: "Good morning Michael, I want dabullishbear 07/23/17 01:53:05 PM
#8218   Peeps have been accumulating AEPP for over a MMMQA 07/23/17 01:50:37 PM
#8217   Volume will be key starting Monday. Let's hope ninersax 07/23/17 01:14:42 PM
#8216   Another look at AEPP's outstanding bullish chart technicals: zen222 07/23/17 01:03:30 PM
#8215   Chart technicals are showing a confirmed bullish trend. zen222 07/23/17 12:49:44 PM
#8214   I stickied Reaper conservative price projection from zen222 Eltp 07/23/17 12:40:09 PM
#8213   I'm just talking by Labor Day microcaptrdr24 07/23/17 11:02:55 AM
#8212   As reaper stated, valuation could be betwwen 100m tmcfo 07/23/17 10:43:49 AM
#8211   Perhaps, but still extremely conservative price projections IMO. zen222 07/23/17 10:32:42 AM
#8210   We should get to .50 on the RM, microcaptrdr24 07/23/17 10:09:04 AM
#8209   Reaper, you are the man..great explanation about many tmcfo 07/23/17 09:58:29 AM
#8208   I don't disagree with you. The chart looks BLight1911 07/23/17 08:57:23 AM
#8207   In all due respect whether we get news seanbc 07/23/17 02:11:36 AM
#8202  Restored LOL, laraz... reaper247 07/22/17 11:15:25 PM
#8201   ONCOLIX IS A CERVICAL/BREAST CANCER DRUG_COMPANY Rat Fink 07/22/17 09:50:13 PM
#8200   WRONG.. respectfully disagree.. BottomWatcher 07/22/17 09:26:16 PM
#8199   When aepp hits $2, l am going to tmcfo 07/22/17 07:40:20 PM
#8198   Yes indeed, as in we are golden here. zen222 07/22/17 05:43:13 PM
#8197   I distinctly notice a golden cross towards the BLight1911 07/22/17 05:16:47 PM
#8196   Better check the AEPP chart since Michael T zen222 07/22/17 05:14:24 PM
#8195   MICHAEL REDMAN IS NOW CEO OF BOTH ONCOLIX_&_AEPP!!!_https://www.otcmarkets.com/stock/AEPP/profil Rat Fink 07/22/17 05:07:32 PM
#8194   Larez Do you even think ocoloix even exists? Breeze123456 07/22/17 04:32:49 PM
#8193   Michael Redman left Repros in 2001 ... molee 07/22/17 04:30:06 PM
#8192   Bad day for any stock when these low laraz5 07/22/17 03:51:14 PM
#8184   reaper247 sure did. It deserves to be reposted: https://investorshub.advfn.com/boards/read_msg.aspx? zen222 07/22/17 12:36:14 AM
#8183   you have a "stellar" weekend too Zen!! I arbytrader 07/22/17 12:29:21 AM
#8181   Haha go get em Zen!!!! I'm going to arbytrader 07/22/17 12:03:06 AM
#8179   Yes, stellar background. As in exemplary or impeccable. zen222 07/21/17 11:57:10 PM
#8178   BK did reverse splits with all his stocks arbytrader 07/21/17 11:49:02 PM
#8177   BK made his 2.8 million and he's out arbytrader 07/21/17 11:40:57 PM
#8175   "Stellar background" can you provide facts to this Airstock 07/21/17 11:35:50 PM
#8174   Amazing day for AEPP... Not sure if it Airstock 07/21/17 11:34:06 PM
#8173   AEPP 3 month chart is looking positively bullish: zen222 07/21/17 10:07:00 PM
#8172   Michael T. Redman is CEO of AEPP, period. zen222 07/21/17 07:39:46 PM
#8171   ONLY "117,359" SHARES TRADED TODAY!!! SHAREHOLDERS_"HOLDING"_THEIR_SHARES!!! Rat Fink 07/21/17 07:09:06 PM
#8170   At this point alot of people defending this Pinky4 07/21/17 06:16:38 PM
#8167   Because this is my 5th rodeo with him. getReady 07/21/17 05:29:23 PM
#8164   Ohhh ok Pinky4 07/21/17 04:58:29 PM
#8163   Im right here with u brother ....we in Pinky4 07/21/17 04:56:58 PM
#8162   6 days to go Sungod95 07/21/17 04:49:52 PM
#8161   Entire week AND one day, the Monday after Sungod95 07/21/17 04:46:43 PM
#8160   Facts Billydakidd 07/21/17 04:45:18 PM
#8159   I'm interested in why you say this. fuzzymcilwoods 07/21/17 04:43:38 PM
#8158   What happened to all the volume this afternoon? KDOG9 07/21/17 04:38:47 PM
#8157   Oh but he is getReady 07/21/17 04:29:51 PM
PostSubject